Clinical Trial Update: AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of cediranib (AZD2171) in patients with refractory metastatic kidney cancer was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-11-20